newsfilter
← Latest News
GlobeNewswire·

Valneva to Report Nine-Month 2026 Consolidated Financial Results on November 24, 2026

  • Valneva SE will report its nine-month 2026 financial results on Tuesday, November 24, 2026.
  • The company will host a live webcast at 3 p.m. CET/9 a.m. ET to discuss financial results & provide a business update.
  • The webcast will be accessible on the company website & archived after the event.
  • Valneva develops, manufactures, & commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs.
  • The company currently markets three proprietary travel vaccines.
  • Valneva's pipeline includes a Lyme disease vaccine candidate partnered with Pfizer that is under regulatory review.
  • The company also has the world's most clinically advanced Shigella vaccine candidate.
  • Investor & media contact persons include Laetitia Bachelot-Fontaine & Joshua Drumm, Ph.D.
  • The press release contains forward-looking statements subject to risks such as regulatory delays, clinical trial outcomes, & currency fluctuations.